Drug Profile
Ranibizumab biosimilar - Paras Biopharmaceuticals
Latest Information Update: 21 Nov 2021
Price :
$50
*
At a glance
- Originator Paras Biopharmaceuticals Finland
- Class Eye disorder therapies; Immunoglobulin fragments; Monoclonal antibodies
- Mechanism of Action Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Age-related macular degeneration
Most Recent Events
- 28 Jun 2019 No recent reports of development identified for research development in Age-related-macular-degeneration in Finland (Parenteral)
- 21 May 2015 Early research in Age-related macular degeneration in Finland (Parenteral) (Paras pipeline, May 2015)